会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 51. 发明申请
    • COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
    • 用于治疗代谢性疾病的化合物
    • WO2004073611A2
    • 2004-09-02
    • PCT/US2004/003718
    • 2004-02-09
    • WELLSTAT THERAPEUTICS CORPORATIONHODGE, Kirvin, L.LEE, AlbertSHARMA, ShaliniVON BORSTEL, Reid, W.
    • HODGE, Kirvin, L.LEE, AlbertSHARMA, ShaliniVON BORSTEL, Reid, W.
    • A61K
    • C07C69/734A61K31/192A61K31/24C07C59/68C07C65/24C07C69/76C07C69/92
    • Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, artherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0, 1, 2, 4 or 5; q is 0 or 1; t is 0 or 1; R 2 is alkyl from 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by or 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloaldyl having from 3 to 6 ring carbon atoms wherein the cycloaldyl is unsubstitited or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compounds of formula (I) by a ring carbon; and R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R 1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
    • 公开了用于治疗各种代谢疾病如胰岛素抵抗综合征,糖尿病,高脂血症,脂肪肝疾病,恶病质,肥胖症,动脉粥样硬化和动脉硬化的药剂。 式(I)其中n为1或2; m为0,1,2,4或5; q为0或1; t为0或1; R 2是1至3个碳原子的烷基; R 3是氢,卤素,具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; A是未取代或被1或2个选自以下的基团取代的苯基:卤素,具有1或2个碳原子的烷基,全氟甲基,具有1或2个碳原子的烷氧基和全氟甲氧基; 或具有3至6个环碳原子的环戊烯基,其中所述环烯基未被取代或一个或两个环碳独立地被甲基或乙基单取代; 或具有1或2个选自N,S和O的环杂原子的5或6元杂芳环,杂芳环通过环碳与其余的式(I)化合物共价结合; 和R 1是氢或具有1或2个碳原子的烷基。 或者,当R 1是氢时,生物活性剂可以是式(I)化合物的药学上可接受的盐。
    • 53. 发明申请
    • TOBACCO SMOKE FILTER FOR REMOVING TOXIC COMPOUNDS
    • 用于去除毒性化合物的烟草烟雾过滤器
    • WO1998015197A1
    • 1998-04-16
    • PCT/US1997008285
    • 1997-05-14
    • LESSER, CraigVON BORSTEL, Reid, W.
    • A24D03/00
    • B01J13/04A24D3/061A24D3/14
    • A tobacco smoke filter comprising a porous substrate having a humectant, such as sodium pyroglutamate, dispersed therein to absorb moisture from the tobacco smoke thereby wet-filtering the tobacco smoke. The tobacco smoke filter can also comprise a porous substrate having microcapsules dispersed therein. The microcapsules can comprise a humectant such as sodium pyroglutamate. The microcapsules further preferably comprise one or more of methylcellulose, chlorophyllin and at least one vegetable oil. The tobacco smoke filter can also comprise a porous substrate having dry water and a porphyrin dispersed therein. The tobacco smoke filter can also comprise a porous substrate having a copper-containing porphyrin dispersed therein.
    • 一种烟草烟雾过滤器,包括具有分散在其中以吸收来自烟草烟雾中的水分的湿润剂如诸如焦谷氨酸钠的多孔底物,从而湿过滤烟草烟雾。 烟草烟雾过滤器还可以包括其中分散有微胶囊的多孔基材。 微胶囊可以包含一种保湿剂,例如焦谷氨酸钠。 微胶囊还优选包含一种或多种甲基纤维素,叶绿素和至少一种植物油。 烟草烟雾过滤器还可以包括具有分散在其中的干燥水和卟啉的多孔基材。 烟草烟雾过滤器还可以包括其中分散有含铜卟啉的多孔基材。